Table 2.

Clinical Trials Evaluating Angiotensin-Converting Enzyme Inhibitors Compared with Diuretic or β-Blocker.

Study EndpointsCAPPP9 RR (95% CI)*STOP-210 RR (95% CI)*
Combined primary endpoint
 Fatal and nonfatal myocardial infarction and stroke, or other cardiovascular deaths1.05 (0.90–1.22)
 Fatal myocardial infarction, fatal stroke, or other fatal cardiovascular disease1.01 (0.84–1.22)
Other endpoints
 Fatal and nonfatal myocardial infarction0.96 (0.77–1.19)0.90 (0.72–1.13)
 Fatal and nonfatal stroke1.25(1.01–1.55)0.90 (0.74–1.08)
 All major cardiovascular events0.94 (0.83–1.06)0.94 (0.82–1.07)
 Cardiovascular mortality0.77 (0.57–1.04)1.01 (0.84–1.22)
 Total morbidity0.93 (0.76–1.14)1.02 (0.89–1.18)
  • RR = relative risk, CI = confidence interval.

  • * Angiotensin-converting enzyme inhibitor compared with diuretic or β-blocker.

  • P = .044.